Back to search

Peptide record

TPDB05392

Polybia-MPI Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard
14 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05392
Polybia-MPI
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb i2APP ToxinPred 3.0
standard
No
A 14-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
IDWKKLLDAAKQIL
Physicochemical Analysis
C78H131N19O20
RNCEGHMFPSTYV
LK
1655.01
9.76
3
2
8
+1
1.52
0.064
153.57
Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour
5500
332.32
1
Residue Composition
number
2
A
0
R
0
N
2
D
0
C
0
E
1
Q
0
G
0
H
2
I
3
L
3
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 2 C: 0 E: 0 Q: 1 G: 0 H: 0 I: 2 L: 3 K: 3 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
14
C78H131N19O20
1655.01
9.76
+1
1.52
0.064
Free
L
Not Available
Free
Antibacterial
venom, social wasp,Polybia paulista
Evidence Records 20 records
Evidence 1 Activity

Activity

MIC
Antibacterial
5 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Activity against G+ and G- bacteria such as E. coli (MIC 5 uM), S. aureus (MIC 9 uM), and B. cereus (MIC 5 uM), and P. aeruginosa (MIC 5 uM). Have anti-
Evidence 2 Activity

Activity

MIC
Antibacterial
9 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP

Other

Activity against G+ and G- bacteria such as E. coli (MIC 5 uM), S. aureus (MIC 9 uM), and B. cereus (MIC 5 uM), and P. aeruginosa (MIC 5 uM). Have anti-biofilm and antifungal
Evidence 3 Activity

Activity

MIC
Antibacterial
5 µM

Target

B. cereus

Source & Reference

dbAMP DRAMP

Other

Activity against G+ and G- bacteria such as E. coli (MIC 5 uM), S. aureus (MIC 9 uM), and B. cereus (MIC 5 uM), and P. aeruginosa (MIC 5 uM). Have anti-biofilm and antifungal activities against C. alb
Evidence 4 Activity

Activity

MIC
Antibacterial
5 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP

Other

bacteria such as E. coli (MIC 5 uM), S. aureus (MIC 9 uM), and B. cereus (MIC 5 uM), and P. aeruginosa (MIC 5 uM). Have anti-biofilm and antifungal activities against C. albicans and C. glabrata ( Wang K
Evidence 5 Activity

Activity

Not Available
Anticancer

Target

Breast Cancer
Not Available
Not Available

Assay & Model

Not Available
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 6 Activity

Activity

MIC
Antifungal
5 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Activity against G+ and G- bacteria such as E. coli (MIC 5 uM), S. aureus (MIC 9 uM), and B. cereus (MIC 5 uM), and P. aeruginosa (MIC 5 uM). Have anti-
Evidence 7 Activity

Activity

MIC
Antifungal
9 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Activity against G+ and G- bacteria such as E. coli (MIC 5 uM), S. aureus (MIC 9 uM), and B. cereus (MIC 5 uM), and P. aeruginosa (MIC 5 uM). Have anti-biofilm and antifungal
Evidence 8 Activity

Activity

MIC
Antifungal
5 µM

Target

B. cereus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Activity against G+ and G- bacteria such as E. coli (MIC 5 uM), S. aureus (MIC 9 uM), and B. cereus (MIC 5 uM), and P. aeruginosa (MIC 5 uM). Have anti-biofilm and antifungal activities against C. alb
Evidence 9 Activity

Activity

MIC
Antifungal
5 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

bacteria such as E. coli (MIC 5 uM), S. aureus (MIC 9 uM), and B. cereus (MIC 5 uM), and P. aeruginosa (MIC 5 uM). Have anti-biofilm and antifungal activities against C. albicans and C. glabrata ( Wang K
Evidence 10 Activity

Activity

MIC
Antiparasitic
5 µM

Target

Escherichia coli

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
Activity against G+ and G- bacteria such as E. coli (MIC 5 uM), S. aureus (MIC 9 uM), and B. cereus (MIC 5 uM), and P. aeruginosa (MIC 5 uM). Have anti-
Evidence 11 Activity

Activity

MIC
Antiparasitic
9 µM

Target

Staphylococcus aureus

Source & Reference

DRAMP

Other

Activity against G+ and G- bacteria such as E. coli (MIC 5 uM), S. aureus (MIC 9 uM), and B. cereus (MIC 5 uM), and P. aeruginosa (MIC 5 uM). Have anti-biofilm and antifungal
Evidence 12 Activity

Activity

MIC
Antiparasitic
5 µM

Target

B. cereus

Source & Reference

DRAMP

Other

Activity against G+ and G- bacteria such as E. coli (MIC 5 uM), S. aureus (MIC 9 uM), and B. cereus (MIC 5 uM), and P. aeruginosa (MIC 5 uM). Have anti-biofilm and antifungal activities against C. alb
Evidence 13 Activity

Activity

MIC
Antiparasitic
5 µM

Target

Pseudomonas aeruginosa

Source & Reference

DRAMP

Other

bacteria such as E. coli (MIC 5 uM), S. aureus (MIC 9 uM), and B. cereus (MIC 5 uM), and P. aeruginosa (MIC 5 uM). Have anti-biofilm and antifungal activities against C. albicans and C. glabrata ( Wang K
Evidence 14 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Rat erythrocytes

Target

Rat erythrocytes

Source & Reference

NA
DBAASP
Structural and functional characterization of two novel peptide toxins isolated from the venom of the social wasp Polybia paulista | Peptides | 2005
Evidence 15 Activity

Activity

62% degranulation
Toxicity
100 µM
Cytotoxic
62% degranulation | 100 | µM | target cell: Rat mast cells

Target

Rat mast cells

Source & Reference

NA
DBAASP
Structural and functional characterization of two novel peptide toxins isolated from the venom of the social wasp Polybia paulista | Peptides | 2005
Evidence 16 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activity and stability of the D-amino acid substituted derivatives of antimicrobial peptide polybia-MPI. | AMB Express | 2016
Evidence 17 Activity

Activity

3.2% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
3.2% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activity and stability of stapled helices of polybia-MP1. | Arch Pharm Res | 2017
Evidence 18 Activity

Activity

<1% Hemolysis
Toxicity
12.5 µM
Hemolytic Cytotoxic
<1% Hemolysis | 12.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activity and stability of stapled helices of polybia-MP1. | Arch Pharm Res | 2017
Evidence 19 Activity

Activity

50% Cell death
Toxicity
>60 µM
Cytotoxic
50% Cell death | >60 | µM | target cell: Mouse fibroblasts NIH 3T3

Target

Mouse fibroblasts NIH 3T3

Source & Reference

NA
DBAASP
A novel analog of antimicrobial peptide Polybia-MPI, with thioamide bond substitution, exhibits increased therapeutic efficacy against cancer and diminished toxicity in mice. | Peptides | 2010
Evidence 20 Activity

Activity

% Hemolysis
Toxicity
1 %
Hemolytic
Hemolytic_activity: [Ref.29075946] <1% hemolysis at 12.5µM, 3.2% hemolysis at 25µM against human red blood cells.

Target

erythrocytes

Source & Reference

NA
DRAMP
Arch Pharm Res. 2017 Dec 40(12):1414-1419.